Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Rivastigmine 5 cm^2 · 1 trial · 1 indication
The Alzheimer's Disease Assessment Scale-Cognitive (ADAS-cog) subscale comprises 11 items summed to a total score ranging from 0 to 70, with lower scores indicating less severe impairment. A negative change indicates an improvement from baseline.
The Alzheimer's Disease Cooperative Study-Instrumental Activities of Daily Living (ADCS-IADL) is a 16 item subscale of the caregiver-based ADCS-IADL scale, developed for the use in dementia studies. The ADCS-IADL total score ranges from 0 to 56, with higher scores indicating less severe impairment. A positive change indicates an improvement from baseline.
| Arm | Type | Description |
|---|---|---|
| Open label: Rivastigmine (5 cm^2 / 10 cm^2) | EXPERIMENTAL | Rivastigmine 5 cm\^2 transdermal patch once a day during the first 4 weeks of open label treatment followed by rivastigmine 10 cm\^2 transdermal patch once a day from week 4 to week 24, 36 or 48. |
| Double blind: Rivastigmine (10 cm^2) | EXPERIMENTAL | Rivastigmine transdermal patch 10 cm\^2 and placebo to rivastigmine 15 cm\^2 once daily for 48 weeks during the double blind period. |
| Double blind: Rivastigmine (15 cm^2) | EXPERIMENTAL | Rivastigmine transdermal patch 15 cm\^2 and placebo to rivastigmine 10 cm\^2 once daily for 48 weeks during double blind period. |
| Extended open label Rivastigmine (10 cm^2) | EXPERIMENTAL | Rivastigmine 10 cm\^2 transdermal patch once a day during 48 weeks open label treatment running in parallel to the double blind period. |
| Name | Type | Description |
|---|---|---|
| Rivastigmine 5 cm^2 | DRUG | 5 cm\^2 transdermal patch |
| Rivastigmine 10 cm^2 | DRUG | 10 cm\^2 transdermal patch. |
| Rivastigmine 15 cm^2 | DRUG | 15 cm\^2 transdermal patch. |
| Placebo to 15 cm^2 patch | DRUG | Placebo of rivastigmine transdermal patch 15 cm\^2. |
| Placebo to 10 cm^2 patch | DRUG | Placebo of rivastigmine transdermal patch 10 cm\^2. |
Inclusion Criteria: * Male or female patients between 50 and 85 years of age with a diagnosis of probable Alzheimers Disease, * Baseline Mini-Mental State Examination (MMSE) score 10-24 inclusive, * A primary caregiver willing to accept responsibility for supervising treatment, assessing the patien...
Top 20 of 24 competitors
Rivastigmine 5 cm^2 is a small molecule being developed for Alzheimer's Disease. It is an investigational treatment studied in patients with probable Alzheimer's Disease, including those showing cognitive decline. The drug is administered as a patch and is intended to address symptoms of this neurological condition.
Rivastigmine 5 cm^2 is developed by Novartis AG, a company traded under the ticker NVS. Novartis is conducting clinical trials to evaluate the safety and efficacy of this patch formulation in patients with Alzheimer's Disease.
Rivastigmine 5 cm^2 is in Phase 3 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The Phase 3 trials are completed, and the drug remains under evaluation for Alzheimer's Disease.
Rivastigmine 5 cm^2 has been studied in two completed Phase 3 trials. NCT00428389 evaluated switching from donepezil to rivastigmine patch in 262 patients. NCT00506415 compared rivastigmine 10 and 15 cm^2 patches in 1584 patients with cognitive decline. Both trials involved Alzheimer's Disease patients aged 50 and older.
Rivastigmine 5 cm^2 refers to a specific patch size of rivastigmine. The clinical trials studied rivastigmine patches of various sizes, including 10 and 15 cm^2. The 5 cm^2 patch is one formulation within this development program for Alzheimer's Disease.